SwePub
Sök i SwePub databas

  Extended search

Träfflista för sökning "WFRF:(Ohlsson A) srt2:(1990-1994)"

Search: WFRF:(Ohlsson A) > (1990-1994)

  • Result 1-6 of 6
Sort/group result
   
EnumerationReferenceCoverFind
1.
  •  
2.
  • Gupta, Sourendu, et al. (author)
  • Finite-size scaling at phase coexistence
  • 1993
  • In: Nuclear Physics, Section B. - 0550-3213. ; 409:3, s. 663-683
  • Journal article (peer-reviewed)abstract
    • From a finite-size scaling (FSS) theory of cumulants of the order parameter at phase-coexistence points, we reconstruct the scaling of the moments. Assuming that the cumulants allow a reconstruction of the free energy density no better than as an asymptotic expansion, we find that FSS for moments of low order is still complete. We suggest ways of using this theory for the analysis of numerical simulations. We test these methods numerically through the scaling of cumulants and moments of the magnetisation in the low-temperature phase of the two-dimensional Ising model.
  •  
3.
  •  
4.
  •  
5.
  •  
6.
  • Sundkvist, Göran, et al. (author)
  • Islet cell antibodies, but not glutamic acid decarboxylase antibodies, are decreased by plasmapheresis in patients with newly diagnosed insulin-dependent diabetes mellitus
  • 1994
  • In: Journal of Clinical Endocrinology and Metabolism. - : The Endocrine Society. - 0021-972X .- 1945-7197. ; 78:5, s. 1159-1165
  • Journal article (peer-reviewed)abstract
    • The effects of plasmapheresis on islet autoantibody levels, C-peptide (β-cell function), and hemoglobin-A1c (HbA1c, metabolic control) were tested in a prospective blinded study of 18 newly diagnosed insulin-dependent diabetes mellitus (IDDM) patients randomly assigned to receive plasmapheresis (P), carried out as double filtration, or sham (S) treatment at diagnosis and 3 months thereafter. At diagnosis, 6 of 8 patients (75%) in group P and 9 of 10 patients (90%) in group S had islet cell antibodies (ICA), whereas 4 of 8 (50%) and 7 of 10 (70%) patients, respectively, had glutamic acid decarboxylase antibodies (GAD65-Ab), with no significant differences between the groups in ICA and GAD65-Ab levels. After 6 months, P patients showed significantly lower ICA levels than S patients (11 ± 6 and 128 ± 47 Juvenile Diabetes Foundation International Units, respectively; P < 0.02) due to an increase in ICA levels in 8 of 9 (88%) of the S patients not seen in P patients (P < 0.002). Concurrently, HbA1c stabilized in P, but not in S, patients and was significantly lower by 24 months (6.58 ± 0.54% vs. 9.76 ± 1.21%; P < 0.05). Moreover, fasting C-peptide increased significantly (214 ± 11 pmol/L; P < 0.05) over the first 6 months in P. After the initial 6 months, ICA levels tended to decrease in all patients and were not detected after 60 months. GAD65-Ab levels were not influenced by plasmapheresis and, also in contrast to ICA, increased significantly (P < 0.05) in the whole study population after 60 months. In fact, 4 initially negative patients became GAD65-Ab positive after diagnosis (in 2 patients > 24 months after diagnosis). We conclude that plasmapheresis of newly diagnosed IDDM patients does not change subsequent GAD65-Ab levels, but ICA are significantly decreased with associated improved C-peptide and HbA1c levels.
  •  
Skapa referenser, mejla, bekava och länka
  • Result 1-6 of 6

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view